scholarly journals Effect of the body weight index on the intensity of metabolic disorders in essential hypertension patients associated with ischemic heart disease and type 2 diabetes mellitus

2019 ◽  
Vol 23 (3 (91)) ◽  
pp. 8-15
Author(s):  
S. V. Biletskyi ◽  
V. V. Boyko ◽  
O. A. Petrynych ◽  
T. V. Kazantseva ◽  
I. V. Marchuk
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Heart Disease ◽  
Essential Hypertension ◽  
Metabolic Disorders ◽  
The Body ◽  
Body Weight Index

scholarly journals Arterial hypertension and type 2 diabetes mellitus in patients with metabolic disorders: Their impact on the lipid spectrum

2003 ◽  
Vol 9 (2) ◽  
pp. 67-70 ◽  
Author(s):  
A. I. Kuzin ◽  
M. A. Cherednikova ◽  
A. A. Vasilyev ◽  
O. V. Kamerer
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Arterial Hypertension ◽  
Metabolic Disorders ◽  
The Body ◽  
Cholesterol Levels ◽  
Type 2 Dm ◽  
Lipid Spectrum

The study was undertaken to examine the specific features of the lipid spectrum in patients with metabolic disorders in the absence or presence of arterial hypertension (AH) and type 2 diabetes mellitus (DM) The study covered 176 patients with metabolic disorders, 138 patients were diagnosed as having AH, of them 39 patients had type 2 DM Clinical and laboratory studies involved the estimation of the body mass index, waist/hip ratio, and lipid spectrum All the patients were divided into 3 groups I) 38 without AH and type 2 DM, 2) 99 with isolated AH without type 2 DM, 3) 39 with AH and type 2 DM The higher severity of abdominal obesity was associated with enhanced dyslipidemia atherogemcity The development of AH m the presence of metabolic disorders was accompanied by higher total cholesterol levels, which may be considered as aggravated endothelial dysfunction Its concurrence with type 2 DM was attended by transformation of metabolic to diabetic dyslipidemia The study has yielded a new index that characterizes dyslipidemia atherogemcity in patients with metabolic disorders

scholarly journals Вплив ураження ацетамінофеном на тлі цукрового діабету типу 2 на зміни показників глутатіонової системи

2018 ◽  
Author(s):  
O. B. Furka
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Antioxidant System ◽  
The Body ◽  
Intraventricular Injection ◽  
Control Group ◽  
Starch Solution

Introduction. The most important function of the liver in the body is neutralization and destruction of toxic substances. Metabolism and utilization of chemical and biological toxins are carried out by neutralizing the hepatocyte system, followed by the removal of harmful products from the body.The aim of the study – to investigate the effect of acetaminophen on the background of type 2 diabetes mellitus on the main parameters of the glutathione unit of the antioxidant system in rat liver homogenate in time dynamics.Research Methods. The experiments were carried out on white mature rats weighing 180–220 g, contained on a standard ration of the vivarium and free access to water. We conducted 2 series of experiments. In the first, toxic acetaminophen was caused by a single intraventricular injection of acetaminophen in 2 % starch solution at a dose of 1250 mg/kg body weight (1/2 LD50), in the second suspension of acetaminophen in a 2 % starch solution at a dose of 55 mg/kg, which corresponds to the highest therapeutic dose for 7 days. The non-genetic form of experimental type 2 diabetes mellitus was modeled according to the method of Islam S., Choi H. (2007) by a single intraperitoneal injection of a streptozotocin solution (“Sigma”, USA) at a body weight (200±20) g at a rate of 65 mg/kg, which diluted with citrated buffer (pH 4.5) with a preliminary (within 15 minutes) intraperitoneal administration of nicotinamide in a dose of 230 mg/kg. For the control group, rats with the same body weight were administered with a similar volume of solvent (citrate buffer pH 4.5).Results and discussion. Activation of lipid peroximation reactions is one of the fundamental biological mechanisms of damage to biostructures and the development of cellular pathology for the actions of damaging factors of various genesis, especially under the conditions of xenobiotics.Conclusion. Acetaminophen poisoning against type 2 diabetes mellitus causes a significant disruption of compensatory mechanisms, especially the state of the enzyme and non-enzyme links of the antioxidant system.

scholarly journals The experience with the use of the GLP-1 analog liraglutide (Victoza) for the optimization of metabolic control and correction of the body mass in the patients with type 2 diabetes mellitus

2012 ◽  
Vol 58 (5) ◽  
pp. 75-79
Author(s):  
T V Saprina ◽  
T K Gudkova ◽  
V A Stoliarova ◽  
S Iu Martynova ◽  
N G Dudar'kova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Risk Factor ◽  
Combined Therapy ◽  
The Body ◽  
Hypoglycemic Agents ◽  
Cardiovascular Risks

The optimal control of diabetes mellitus (DM) should ensure not only the achievement and maintenance of the targeted blood glucose level but also the reduction of other cardiovascular risks. Obesity is a key risk factor of the development of type 2 diabetes mellitus (DM2) and an independent risk factor of cardiovascular complications. The agonists of glucagon-like peptide-1 (GLP-1) are currently considered to be the sole hypoglycemic agents that not only effectively correct hyperglycemia but also reduce the excessive body weight. Liraglutide (Victoza, Novo Nordisk) is the first long-acting analog of human GLP-1 approved for the application in the treatment of DM2 at the early stages of the disease in the form of both mono- and combined therapy. We present the literature review of the results of randomized clinical studies and our own experience with the use of Victoza for glycemic control and correction of the body weight in the patients presenting with type 2 diabetes mellitus.

scholarly journals Bronchial asthma in the genetic framework of cardiovascular continuum syntropy

2022 ◽  
Vol 36 (4) ◽  
pp. 52-61
Author(s):  
E. Yu. Bragina ◽  
I. A. Goncharova ◽  
I. Zh. Zhalsanova ◽  
E. V. Nemerov ◽  
M. S. Nazarenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Heart Disease ◽  
Type 2 Diabetes Mellitus ◽  
Heart Disease ◽  
Bronchial Asthma ◽  
Metabolic Disorders ◽  
Cardiometabolic Disorders ◽  
Cardiovascular Continuum

Hypertension, coronary heart disease, myocardial infarction, obesity, and type 2 diabetes mellitus are common comorbidities in patients with bronchial asthma. The causes for developing these diseases are multifactorial and involve inherited genetic factors. However, little is known about the genes contributing to the development of comorbidities in bronchial asthma and cardiovascular disease continuum.Objective. To examine the associations of genetic polymorphic variants potentially involved in the development of bronchial asthma comorbid with hypertension, coronary heart disease, type 2 diabetes mellitus, and obesity.Material and Methods. Genotyping of 92 single nucleotide polymorphisms (SNPs) was performed using MALDI-TOF mass spectrometry in patients with bronchial asthma associated with cardiovascular/metabolic disorders (n = 162) compared with a control group of apparently healthy individuals (n = 153).Results. The development of bronchial asthma phenotypes comorbid with cardiovascular/metabolic disorders was associated with the particular genetic variants affecting the expression of genes including CAT, TLR4, ELF5, ABTB2, UTP25, TRAF3IP3, NFKB1, LOC105377347, C1orf74, IRF6, and others in the target organs of study disease profile. Only one SNP (rs11590807), which is regulatory for the UTP25, IRF6, TRAF3IP3, and RP1-28O10.1 genes, was associated with all studied comorbid phenotypes of bronchial asthma and diseases of cardiovascular continuum.Conclusion. The obtained results demonstrated that the identified SNPs affecting the expression of many genes may serve as potential biological markers of complex causal relationships between bronchial asthma and cardiometabolic disorders.

Sign in / Sign up

Export Citation Format

Share Document